Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RNF4 | P78317 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495185 | 0.91 | CYP3A4 (0.39) | CYP2D6TSHR | |
| SCHEMBL16495184 | 0.89 | SLC22A12 (0.39) | MAPTSIGMAR1 | |
| SCHEMBL16495403 | 0.86 | BCHE (0.39) | ACHEMAPTTP53PTGDR2 | |
| SCHEMBL16494548 | 0.78 | ACHE (0.54) | ACHEMAPT | |
| SCHEMBL16495217 | 0.77 | HDAC1 (0.35) | ACHETP53OPRM1OPRL1TSHR | |
| SCHEMBL16494772 | 0.74 | ALDH1A1 (0.52) | ACHEMAPT | |
| SCHEMBL16495104 | 0.73 | NPC1 (0.39) | TP53OPRM1OPRL1TSHRSIRT1 | |
| SCHEMBL16495089 | 0.73 | ACHE (0.57) | ACHE | |
| SCHEMBL16495115 | 0.73 | CACNA1G (0.37) | ACHEMAPT | |
| SCHEMBL16494726 | 0.72 | SIGMAR1 (0.44) | OPRM1SIGMAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | ACHE 2/4885MAPT 2067/4885RNF4 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.